Bristol-myers Squibb Stock News

Cahaba Wealth Management Inc. bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,778 shares of the biopharmaceutical companys stock, valued at approximately $223,000. A number of other institutional investors and hedge funds also []

Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.

The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The European Medicines Agency has also

Dividend boosts in the latter half of November were as expected, but with some surprises.

Bristol-Myers has seen a relatively uneventful 2021 after the Celgene and MyoKardia deal.

Bristol-Myers Squibb Company (BMY) with the stream of -0.49% also noticed, India Avino Silver & Gold Mines Ltd. (ASM) encountered a rapid change of -3.42% in the last hour of The post This Stocks might change the Kismet of Investors: Bristol-Myers Squibb Company (NYSE:BMY), Avino Silver & Gold Mines Ltd. (AMEX:ASM) appeared first on Stocks Equity .

Crossmark Global Holdings Inc. cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 82.8% in the third quarter, HoldingsChannel reports. The firm owned 8,640 shares of the biopharmaceutical companys stock after selling 41,539 shares during the period. Crossmark Global Holdings Inc.s holdings in Bristol-Myers Squibb were worth $292,000 as of its most recent SEC []

Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.

Peoples Financial Services CORP. decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,129 shares of the biopharmaceutical companys stock after selling 804 shares during the period. Bristol-Myers Squibb accounts for about 1.1% of Peoples Financial []

Appleton Partners Inc. MA lifted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 12,684 shares of the biopharmaceutical companys stock after buying an additional 892 shares during the quarter. Appleton Partners Inc. MAs holdings in Bristol-Myers []

Bristol-Myers Squibb (NYSE:BMY) EVP Autenried Paul Von sold 17,353 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, November 24th. The stock was sold at an average price of $56.92, for a total value of $987,732.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this []

Although crashes are inevitable, they're the perfect time to buy great businesses at a discount.

Bristol-Myers Squibb Co. (BMY) shares closed today at 0.7% above its 52 week low of $56.11, giving the company a market cap of $126B. The stock is currently down 6.3% year-to-date, down 6.7% over the past 12 months, and up 14.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 45.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -148.4% The company's stock price performance over the past 12 months lags the peer average by -138.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The brain is surrounded by protective fluid known as cerebrospinal fluid and a protective membrane called the meninges. Blood brain barrier is another protective element present between the brain''s blood vessels, and the cells and other components that together make

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).